Those who cover green and sustainability issues know that Pharma is pretty progressive. No, the industry's not perfect, certainly, but many of its leading companies also make it a point to be leaders in environmental stewardship.
The news today that DSM Biologics and Crucell N.V. had again scaled up production of the PER.C6 cell line was another sign that biopharma cell culture capacity concerns are (probably) a thing of the past, and that PER.C6 represents a breakthrough.
Karen King, President of DSM Biologics, discussed the implications of the company's recent joint venture with Crucell, which has increased upstream productivity. The technology, PER.C, has reportedly boosted fermentation yields in human cells to over 27 grams/L compared with 15 g/L a few months ago.
Just filing a few more notes on the Yale Green Processing conference from last week. Afternoon sessions during the first day focused on the "hot" topic of continuous processing and use of process intensification to improve reaction chemistry.